 Shares of Blueprint Medicines NASDAQ:BPMC remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share fell 11.76 over the past year to 2.28, which missed the estimate of 2.14.Revenue of 8,343,000 up by 63.27 year over year, which beat the estimate of 6,600,000.Outlook Blueprint Medicines hasnt issued any earnings guidance for the time being.Blueprint Medicines hasnt issued any revenue guidance for the time being.Details Of The Call Date: Jul 30, 2020View more earnings on BPMCTime: 08:30 AMET Webcast URL: Stock Performance Companys 52-week high was at 101.7652-week low: 43.29Price action over last quarter: Up 22.55Company Overview Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.See more from Benzinga Recap: Molson Coors Beverage Q2 Earnings A.O. Smith: Q2 Earnings Insights Textron: Q2 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 